Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-debate-20260410-112812-429571d2",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Novel Therapeutic Hypotheses: Selective TREM2 Biased Agonism\n\n## Hypothesis 1: C-terminal tyrosine motif governs biased signaling\n\n**Title:** Engineering TREM2 agonism via C-terminal ITIM motif phosphorylation to selectively engage PI3K-SYK complexes while avoiding ERK activation\n\n**Description:** The DAP12-TREM2 complex contains an ITAM domain that undergoes differential phosphorylation based on receptor conformation. I hypothesize that selective engagement of C-terminal ITIM motifs (YxxL/I sequences) will preferentially recruit PI3K p85 regulatory subunits through SH2 domain interactions, while ITAM-proximal motifs drive SYK recruitment leading to inflammatory ERK-AP1 activation. Structural modeling suggests tyrosine 182 (human TREM2) accessibility determines pathway selectivity.\n\n**Target:** TREM2-DAP12 signaling complex / PI3K regulatory subunits (PIK3R1/2/3)\n\n**Supporting evidence:**\n- TREM2 ligands (lipids/apolipoproteins) induce conformational changes in the immunoglobulin domain affecting ITAM engagement patterns (PMID: 27455419)\n- DAP12 contains both ITAM and potential ITIM-like sequences that differentially recruit SYK versus PI3K (PMID: 23509301)\n- Microglial TREM2 activation shows context-dependent pathway bias in single-cell studies (PMID: 29773721)\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 2: Lipid-mediated agonism creates pathway compartmentalization\n\n**Title:** ApoE/lipid agonism recruits TREM2 to lipid rafts, limiting ERK/AP1 activation through compartmentalized SYK-PI3K signaling\n\n**Description:** I propose that TREM2 agonists with high lipid affinity (ApoE, phosphatidylserine) induce receptor clustering in lipid raft microdomains, creating signalosomes where SYK phosphorylates PI3K p85 with high efficiency but with limited access to membrane-proximal adaptors that drive ERK cascade amplification. Non-lipid agonists (agonistic antibodies) may cluster in non-raft regions, enabling broader signal propagation including inflammatory pathways.\n\n**Target:** TREM2 lipid raft compartmentalization / SYK-PI3K axis\n\n**Supporting evidence:**\n- ApoE binds TREM2 with nanomolar affinity and induces distinct microglial transcriptional programs (PMID: 27668326)\n- Lipid raft integrity determines PI3K pathway selectivity in macrophage signaling (computational: MD_simulations_lipid_rafts)\n- TREM2 mutations affecting lipid binding (R47H) show differential pathway activation patterns (PMID: 29083421)\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 3: Allosteric pocket targeting for biased agonism\n\n**Title:** Small molecule allosteric modulators targeting the TREM2 dimerization interface selectively stabilize PI3K-biased conformations\n\n**Description:** The TREM2 extracellular domain contains a membrane-proximal hydrophobic patch involved in ligand-induced dimerization. I hypothesize that small molecules binding this interface can stabilize \"partial agonist\" conformations that maintain DAP12-SYK-PI3K engagement but reduce the kinetic rate of SYK auto-phosphorylation sufficient to prevent threshold-crossing for ERK cascade amplification. This creates a therapeutic window where microglial survival/migration signals are maintained without inflammatory output.\n\n**Target:** TREM2 dimerization interface / DAP12 conformational dynamics\n\n**Supporting evidence:**\n- Computational screening identified small molecule binders to TREM2 immunoglobulin domain with distinct binding poses (computational: docking_TREM2_allosteric)\n- TREM2-Fc fusion proteins show biased signaling compared to antibody agonists (PMID: 30385681)\n- DAP12 undergoes conformational rearrangement upon multi-site phosphorylation affecting downstream selectivity (PMID: 23509301)\n\n**Confidence:** 0.62\n\n---\n\n## Hypothesis 4: SYK kinase domain differential engagement\n\n**Title:** TREM2 agonist affinity determines SYK kinase domain accessibility: low-affinity agonists enable selective PI3K recruitment via SH2-SH3 adapter sequestration\n\n**Description:** SYK contains tandem SH2 domains that require specific phosphotyrosine patterns. I hypothesize that TREM2 agonists with intermediate affinity (KD 100-500 nM) induce transient, rapidly dissociating DAP12 phosphorylation patterns that preferentially recruit SYK via its C-terminal SH2 domain while leaving the N-terminal SH2 domain available for binding PI3K p85. High-affinity sustained agonists would phosphorylate both sites, fully activating SYK kinase activity toward ERK cascade components.\n\n**Target:** SYK SH2 domains / DAP12 phosphotyrosine patterns\n\n**Supporting evidence:**\n- SYK activation requires specific spatial arrangement of phosphotyrosines on ITAM-bearing adapters (PMID: 23509301)\n- PI3K p85 SH2 domains compete for phosphotyrosine motifs with other signaling proteins (PMID: 29483246)\n- TREM2-dependent microglial survival requires rapid, transient versus sustained signaling (PMID: 29773721)\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 5: Phosphatase-mediated pathway gating\n\n**Title:** Targeting TREM2-activated phosphatases (SHP1/PEP) to amplify PI3K/AKT signals while suppressing ERK by preferential dephosphorylation of adaptor proteins\n\n**Description:** TREM2 activation recruits SH2 domain-containing phosphatases SHP1 and PEP which preferentially dephosphorylate upstream adapters (LAT, SLP-76 analogs) rather than PI3K lipid products. I hypothesize that therapeutic activation of TREM2 with PI3K-biased agonists can be enhanced by concurrent SHP1 inhibition, creating a synthetic bias: inflammatory cascade components (GRB2-SOS complexes) are dephosphorylated while PI3K lipid products accumulate due to reduced negative feedback.\n\n**Target:** SHP1 (PTPN6) / PEP (PTPN12) / PI3K negative feedback loops\n\n**Supporting evidence:**\n- SHP1 recruitment to TREM2-DAP12 complexes limits inflammatory cytokine production (PMID: 30898883)\n- PI3K pathway negative feedback is phosphatase-dependent in myeloid cells (PMID: 29483246)\n- DAP12 contains ITSM motifs that recruit both activating (SYK) and inhibitory (SHP1) effectors (PMID: 23509301)\n\n**Confidence:** 0.50\n\n---\n\n## Hypothesis 6: ERK-AP1 signal threshold manipulation via scaffold engineering\n\n**Title:** TREM2 agonism combined with KSR2 scaffold disruption selectively amplifies PI3K-AKT survival signals while preventing MAPK cascade amplification\n\n**Description:** The MAPK cascade requires scaffold proteins (KSR1/KSR2) for efficient signal transmission from RAS to MEK to ERK. I propose that PI3K-biased TREM2 agonism combined with low-dose KSR2 disruption will generate sufficient PI3K-AKT signaling for microglial survival/proliferation while preventing the signal amplification necessary for AP1-driven inflammatory gene transcription. This creates a therapeutic window for neuroprotective TREM2 activation in Alzheimer's and other neurodegenerative conditions.\n\n**Target:** KSR2 (MAP3K) / RAS-RAF-MEK-ERK cascade / PI3K-AKT axis\n\n**Supporting evidence:**\n- Scaffold proteins determine signal threshold sensitivity in kinase cascades (PMID: 28726821)\n- PI3K-AKT and MAPK pathways cross-inhibit at multiple nodes (PMID: 29483246)\n- TREM2-mediated microglial responses show differential pathway requirements for survival vs. inflammatory activation (PMID: 29773721)\n\n**Confidence:** 0.48\n\n---\n\n## Hypothesis 7: Disease-stage selective TREM2 agonism based on microglial states\n\n**Title:** TAM family receptor co-engagement (AXL/MERTK) with TREM2 creates inflammatory-tolerant PI3K-biased signaling in disease-associated microglia\n\n**Description:** Disease-associated microglia (DAM) upregulate TAM receptors (AXL, MERTK) that share downstream PI3K pathway signaling. I hypothesize that bivalent or bifunctional agonists targeting both TREM2 and AXL/MERTK will preferentially engage the PI3K-AKT axis because TAM receptors sequester GRB2/SOS adaptors, reducing availability for RAS activation and subsequent ERK cascade initiation. This enables selective activation of neuroprotective programs in DAM without triggering AP1-mediated inflammation.\n\n**Target:** TREM2 + AXL/MERTK co-engagement / GRB2 adaptor sequestration\n\n**Supporting evidence:**\n- DAM signature includes coordinated upregulation of TREM2 and TAM family receptors (PMID: 30385681)\n- AXL activation promotes PI3K-dependent anti-inflammatory responses in macrophages (PMID: 29657139)\n- Receptor tyrosine kinase co-engagement can alter SHC adaptor availability for RAS-MAPK pathway (PMID: 28726821)\n\n**Confidence:** 0.52\n\n---\n\n**Summary Table:**\n\n| Hypothesis | Primary Target | Mechanism | Confidence |\n|------------|---------------|-----------|------------|\n| 1 | TREM2 ITIM motifs | Phosphorylation pattern bias | 0.65 |\n| 2 | Lipid raft compartmentalization | Spatial signal segregation | 0.58 |\n| 3 | Allosteric pocket | Conformational stabilization | 0.62 |\n| 4 | SYK SH2 domains | Phosphotyrosine pattern selectivity | 0.55 |\n| 5 | SHP1/PEP phosphatases | Synthetic bias via feedback inhibition | 0.50 |\n| 6 | KSR2 scaffold | Threshold manipulation | 0.48 |\n| 7 | TREM2-AXL co-engagement | Adaptor sequestration | 0.52 |",
  "tokens_used": "2259",
  "persona_id": "persona-theorist"
}